fb-pixelThe Latest in Financial & Business News - The Boston Globe Zum Hauptinhalt springen
shirley leung

Celtics star Jaylen Brown is setting out to generate $5 billion in generational wealth for communities of color

The NBA Finals MVP has tapped local partners from MIT to the City of Boston to help shape his vision to support entrepreneurs in the so-called creative economy.

Moderna sinks as outlook cut on low vaccine sales view
The company now sees 2024 sales ranging between $3 billion and $3.5 billion, down from its previous outlook of about $4 billion, according to its second-quarter earnings statement released Thursday.

Biogen raises earnings forecast on Leqembi sales
The rollout of new products, including the closely watched Alzheimer’s drug, helped make up for declining sales of the Cambridge biotech’s multiple sclerosis treatments.

Lilly loses $120 billion in value as rival obesity drugs impress
The company’s shares fell as much as 6.2 percent on Thursday, hitting the lowest intraday level since May. They’re down 14 percent over the past eight trading sessions, their worst eight-day stretch since 2020.

What is the price tag to keep the biotech engine humming in Massachusetts?
Governor Deval Patrick bought us a Ferrari in 2008, when he signed a law allocating $1 billion to the industry over a decade. Now Beacon Hill needs to insure, maintain, and gas up that Ferrari.

The company that spawned Moderna just raised $3.6 billion to back more big ideas in life sciences
Flagship scours labs, research hospitals, and universities for cutting-edge science and builds companies around that science.

Eli Lilly agrees to buy Waltham-based biotech Morphic in $3.2 billion deal
The company will pay $57 a share in cash for Morphic, or 79 percent more than the closing price Friday.

Vertex to stay at Fan Pier headquarters after all
Vertex, the most valuable homegrown biotech in the state, had for months been considering vacating its 1.1 million-square-foot headquarters in the Seaport neighborhood.

More Life Sciences Headlines

AbbVie to buy Cambridge biotech Celsius for $250 million

Privately held Celsius has developed an experimental drug for inflammatory bowel disease.

Moderna just opened its new headquarters in Cambridge. Take a look inside.

The company's COVID vaccine put it on the map, and it hopes bringing its work force together at the new site spurs further discoveries.

Ginkgo Bioworks plans to lay off more than a third of its workers

Based on the headcount reported by the company for the end of last year, at least 400 workers could lose their jobs.

Alnylam shares surge as biotech trumpets positive trial results of heart disease drug

Shares of Alnylam climbed at least 37 percent in pre-market trading Monday morning on the prospect of a drug that could generate billions of dollars for the Cambridge company.

Sarepta jumps on broad approval for muscular dystrophy drug

Sarepta's gene therapy received expanded US approval to include more children with a deadly muscle disease.

Ginkgo Bioworks lays off 158 employees, with more to come

The once-fast-growing life sciences firm is slashing expenses amid financial woes.

RI BUSINESS

R.I. Life Science Hub picks interim president

Patrice Milos, who has 30 years of experience in the life science industry and was a founding member of RI Bio, will make $25,000 a month as the board searches for a permanent CEO.

Moderna’s flu-COVID combo shot hits goal in late-stage trial

The result brings the Cambridge-based company one step closer to a more convenient jab that could help combat vaccine fatigue.